These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26919548)

  • 1. Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
    Cattaneo D; Riva A; Clementi E; Milazzo L; Gervasoni C
    Ther Drug Monit; 2016 Jun; 38(3):285-7. PubMed ID: 26919548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
    Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
    Sulkowski MS; Eron JJ; Wyles D; Trinh R; Lalezari J; Wang C; Slim J; Bhatti L; Gathe J; Ruane PJ; Elion R; Bredeek F; Brennan R; Blick G; Khatri A; Gibbons K; Hu YB; Fredrick L; Schnell G; Pilot-Matias T; Tripathi R; Da Silva-Tillmann B; McGovern B; Campbell AL; Podsadecki T
    JAMA; 2015 Mar 24-31; 313(12):1223-31. PubMed ID: 25706092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
    King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
    Pineda JA; Rivero-Juárez A; de Los Santos I; Collado A; Merino D; Morano-Amado LE; Ríos MJ; Pérez-Pérez M; Téllez F; Palacios R; Pérez AB; Mancebo M; Rivero A; Macías J
    HIV Clin Trials; 2018 Feb; 19(1):23-30. PubMed ID: 29447085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
    Polepally AR; King JR; Ding B; Shuster DL; Dumas EO; Khatri A; Chiu YL; Podsadecki TJ; Menon RM
    Clin Pharmacokinet; 2016 Aug; 55(8):1003-14. PubMed ID: 26895022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
    Menon RM; Badri PS; Wang T; Polepally AR; Zha J; Khatri A; Wang H; Hu B; Coakley EP; Podsadecki TJ; Awni WM; Dutta S
    J Hepatol; 2015 Jul; 63(1):20-9. PubMed ID: 25646891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
    Liu CH; Liu CJ; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2018 Mar; 33(3):710-717. PubMed ID: 28762541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
    Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
    J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
    Lemaitre F; Ben Ali Z; Tron C; Jezequel C; Boglione-Kerrien C; Verdier MC; Guyader D; Bellissant E
    Ther Drug Monit; 2017 Aug; 39(4):305-307. PubMed ID: 28700519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
    Pockros PJ; Reddy KR; Mantry PS; Cohen E; Bennett M; Sulkowski MS; Bernstein DE; Cohen DE; Shulman NS; Wang D; Khatri A; Abunimeh M; Podsadecki T; Lawitz E
    Gastroenterology; 2016 Jun; 150(7):1590-1598. PubMed ID: 26976799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4.
    Abad S; Vega A; Hernández E; Mérida E; de Sequera P; Albalate M; Macías N; Milla M; López-Gómez JM
    Am J Nephrol; 2017; 45(3):267-272. PubMed ID: 28166520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
    Polepally AR; Dutta S; Hu B; Podsadecki TJ; Awni WM; Menon RM
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):269-77. PubMed ID: 27310328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV
    J Viral Hepat; 2018 Oct; 25(10):1180-1188. PubMed ID: 29660224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
    Chan HL; Tsang OT; Hui YT; Fung J; Lui GC; Lai CL; Wong GL; Chan KH; But DY; Lai MS; Lao WC; Chan CK; Lam YS; Seto WK; Li C; Yuen MF; Wong VW
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1230-1233. PubMed ID: 27869328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey.
    Yaraş S; Üçbilek E; Özdoğan O; Ateş F; Altıntaş E; Sezgin O
    Turk J Gastroenterol; 2019 Apr; 30(4):331-335. PubMed ID: 30666967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
    Welzel TM; Asselah T; Dumas EO; Zeuzem S; Shaw D; Hazzan R; Forns X; Pilot-Matias T; Lu W; Cohen DE; Feld JJ
    Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):494-500. PubMed ID: 28416221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
    Gamal N; Andreone P
    Drugs Today (Barc); 2015 May; 51(5):303-14. PubMed ID: 26097903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
    King JR; Menon RM
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):201-205. PubMed ID: 28263457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
    Khatri A; Menon RM; Marbury TC; Lawitz EJ; Podsadecki TJ; Mullally VM; Ding B; Awni WM; Bernstein BM; Dutta S
    J Hepatol; 2015 Oct; 63(4):805-12. PubMed ID: 26070406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.